| Recipient age (years): |
|
| – 18–34 |
276 (13.8) |
| – 35–64 |
1447 (72.1) |
– 65–84
|
285 (14.2)
|
Recipient weight (kg) at transplant
|
81.8 (69.0–95.5)
|
Male sex
|
1261 (62.8)
|
| Race (self-reported): |
|
| – White/Caucasian |
1533 (76.3) |
| – African–American |
373 (18.6) |
| – Asian |
55 (2.8) |
| – Native American/Aleutian Islander |
31 (1.5) |
| – Multiracial |
10 (0.5) |
| – Hawaiian/Pacific Islander |
4 (0.2) |
– Not specified
|
2 (0.1)
|
| Cause of kidney disease: |
|
| – Diabetes |
606 (30.2) |
| – Glomerular disease |
441 (22.0) |
| – Other |
359 (17.9) |
| – Hypertension |
275 (13.7) |
| – Polycystic kidney disease |
262 (13.1) |
– Unknown
|
65 (3.2)
|
Diabetes at time of transplant
|
780 (38.8)
|
Prior kidney transplant
|
295 (14.7)
|
Simultaneous kidney/pancreas
|
157 (7.8)
|
| Donor age (years): |
|
| – 0–34 |
696 (34.7) |
| – 35–64 |
1254 (62.5) |
– 65–84
|
58 (2.9)
|
Deceased donor
|
838 (41.7)
|
| Cytomegalovirus antibody status pretransplant: |
|
| – Negative recipient/negative donor |
415 (21.3) |
| – Positive recipient/negative or positive donor |
1217 (62.6) |
– Negative recipient/positive donor
|
313 (16.1)
|
| Induction immunosuppression: |
|
| – Combination |
54 (2.7) |
| – IL-2 receptor antagonists (basiliximab, daclizumab) |
410 (20.4) |
| – Monoclonal antibodies (OKT3, alemtuzumab, rituximab) |
402 (20.0) |
| – None |
72 (3.6) |
– Polyclonal antibody (antithymocyte globulin)
|
1070 (53.3)
|
| Dialysis after transplant |
179 (8.9) |
